Bio-Rad Laboratories (BIO) Receivables - Net (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Receivables - Net for 18 consecutive years, with $441.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Net fell 5.98% year-over-year to $441.8 million in Q2 2026; TTM through Jun 2026 was $441.8 million, a 5.98% decrease from a year earlier, with the FY2025 full-year figure at $460.6 million, up 1.79% from the prior year.
• Receivables - Net was $441.8 million for Q2 2026 at Bio-Rad Laboratories, up from $426.2 million in the prior quarter.
• Over five years, Receivables - Net peaked at $498.3 million in Q1 2023 and troughed at $424.7 million in Q1 2025.
• A 5-year average of $459.5 million and a median of $459.0 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net rose 16.79% in 2022 and declined 10.73% in 2024, its largest moves.
• Over 5 years, Receivables - Net stood at $494.6 million in 2022, then fell by 1.14% to $489.0 million in 2023, then slipped by 7.46% to $452.5 million in 2024, then advanced by 1.79% to $460.6 million in 2025, then slipped by 4.08% to $441.8 million in 2026.
• The last three Receivables - Net figures came in at $441.8 million (Q2 2026), $426.2 million (Q1 2026), and $460.6 million (Q4 2025), per Business Quant data.